title: Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with alpha/beta hepatosplenic T-cell non-Hodgkin's lymphoma.
abstract: Hepatosplenic T-cell non-Hodgkin's lymphoma (HSTCL) is a rare, aggressive form of NHL, with a median survival of approximately 8 months. We were able to successfully induce complete remission in a patient with alpha/beta HSTCL who was refractory to multiple prior chemotherapy regimens, using the humanized anti-CD52 monoclonal antibody alemtuzumab (Campath). Once disease was controlled, the patient was able to undergo allogeneic stem cell transplantation (SCT), which resulted in complete remission. Furthermore, upon relapse, we were able to re-induce complete clinical and molecular remission with donor lymphocyte infusions. At Day 655 (post-SCT), the patient remains in complete remission. These data suggest a potential role for alemtuzumab and allogeneic SCT in the treatment of T-cell NHL.
authors.affiliation: Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA. asher.chanan-khan@roswellpark.org
authors.forename: Asher
authors.initials: A
authors.lastname: Chanan-Khan
authors.forename: Tariq
authors.initials: T
authors.lastname: Islam
authors.forename: Arif
authors.initials: A
authors.lastname: Alam
authors.forename: Kena C
authors.initials: KC
authors.lastname: Miller
authors.forename: John
authors.initials: J
authors.lastname: Gibbs
authors.forename: Maurice
authors.initials: M
authors.lastname: Barcos
authors.forename: Myron S
authors.initials: MS
authors.lastname: Czuczman
authors.forename: Pamela
authors.initials: P
authors.lastname: Paplham
authors.forename: Theresa
authors.initials: T
authors.lastname: Hahn
authors.forename: Philip
authors.initials: P
authors.lastname: McCarthy
mesh_terms: D000328:Adult; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D008113:Liver Neoplasms / Q000378:metabolism / Q000401:mortality / Q000628:therapy*; D017710:Lymphocyte Transfusion; D016399:Lymphoma, T-Cell / Q000378:metabolism / Q000401:mortality / Q000628:therapy*; D008297:Male; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000378:metabolism; D012074:Remission Induction; D016879:Salvage Therapy; D013160:Splenic Neoplasms / Q000378:metabolism / Q000401:mortality / Q000628:therapy*; D033581:Stem Cell Transplantation; D015996:Survival Rate; D013997:Time Factors; D014019:Tissue Donors; D014182:Transplantation, Autologous
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D016693:Receptors, Antigen, T-Cell, alpha-beta; D000074323:Alemtuzumab